ABSTRACT
INTRODUCTION
Congenital uterine anomalies arise owing to abnormal development of the Müllerian ducts during embryogenesis and have been associated with reduced fertility, miscarriage, preterm birth and other adverse fetal outcomes [1] [2] [3] [4] . Various classification systems have been developed, of which the system of the American Fertility Society (AFS) is the most widely used 5 , but it was introduced without morphometric criteria, making differentiation between anomalies difficult. However, other classifications and criteria to supplement the AFS system have since been proposed 6 . A new system has been developed recently by the European Society of Human Reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE), but this system is not in widespread use and does not allow comparison with previous studies, as the arcuate category has been removed 7 . Indeed, some have argued that the ESHRE-ESGE system is illogical 8 . The diagnosis of uterine anomalies can be achieved using various tests; traditionally, hysteroscopy, hysterosalpingography and clinical examination during surgery have been used, but all three methods are invasive. Optimal diagnosis requires simultaneous viewing of the external contour of the uterus and the endometrial cavity, which can be achieved via combined hysteroscopy and laparoscopy, magnetic resonance imaging or three-dimensional (3D) sonography 9 . 3D ultrasound assessment of uterine morphology was described over 20 years ago 10 . This method is non-invasive, enables accurate full diagnosis and classification of uterine anomaly subtypes, and has been recommended as the reference standard by ESHRE 11, 12 . Saline contrast sonohysterography is more invasive, but has been shown to be accurate, especially when used in conjunction with 3D sonography.
Evidence suggests that uterine anomalies might be associated with a detrimental effect on fertility and increased rates of miscarriage and preterm birth 13 . Nonetheless, given the variations in diagnosis and classification, the true effect of anomalies on reproductive outcome is uncertain. No previous studies have investigated the effect of congenital uterine anomalies on live-birth outcome following assisted reproduction.
The aims of this study were to assess the prevalence of congenital uterine anomalies, including arcuate uterus, in women undergoing assisted reproduction and their effect on the rate of live birth and other pregnancy outcomes.
METHODS
This study was designed to assess the prevalence of congenital uterine anomalies in women undergoing assisted reproduction, and followed similar methods to those of a previous study carried out at our center 14 . Reproductive outcome data were subsequently collected to allow secondary analysis of the effect of congenital uterine anomalies on reproductive outcome.
The study was approved by the local ethics committee and the hospital's research and development department (Ref 06/MRE04/33).
Participants and setting
Consecutive women were recruited prospectively between May 2009 and November 2015 during their initial assessment for subfertility, defined as failure to conceive after regular unprotected sexual intercourse for 2 years. The study was conducted at the Nurture Fertility department of the Fertility Partnership.
Initial assessment included history taking, baseline measurement of anti-Müllerian hormone (AMH) levels and transvaginal sonography (TVS). Since the 3D-TVS scan was part of the diagnostic work-up, no additional consent was required. Patients were excluded if simultaneous assessment of the endometrial cavity and external contour of the uterus was not possible, prohibiting a definitive diagnosis. Reasons for this included the presence of fibroids, intrauterine device or polyps distorting the cavity, Asherman's syndrome, previous hysteroscopic surgery and/or poor quality of images.
Sample-size calculation for studies of rare conditions requires greater precision than the 5% recommended for conditions with a prevalence of between 0.1% and 0.9% 15 . A sample-size calculation was performed based on the expected prevalence from previous meta-analyses. To detect an anomaly with a prevalence of 0.5% with a precision of 0.3%, we calculated that a sample size of 2124 participants would be needed. No a-priori sample-size calculation was performed for secondary analyses.
Three-dimensional ultrasound technique
The TVS technique used to assess uterine morphology has been described previously in detail 16 . Sonographic assessment was performed during the early follicular phase (days 2-5) of the menstrual cycle using a Voluson E8 (GE Medical Systems, Zipf, Austria) with a 5-9-MHz endocavitary transducer. If the initial examination was inconclusive and a definitive diagnosis could not be made, the ultrasound scan was repeated in the late follicular phase (days [10] [11] [12] [13] [14] . The women were scanned either in a modified Lloyd-Davies position with their legs supported by stirrups to allow free manipulation of the TVS transducer or in the dorsal recumbent position using free manipulation and B-mode to allow complete visualization of the uterus. The scans were performed by seven sonographers (M.P., S.A., J.C., L.P., M.P.L., L.F., A.R.), all of whom had received training in 3D ultrasound and in the classification of uterine anomalies and followed the standard operating procedure of the department. The median experience of 3D ultrasound was 5 years (range, 2-6 years). If there was any doubt about the normality of the uterus or the type of anomaly, the diagnosis was reviewed by a second sonographer (N.R.F.).
An initial two-dimensional (2D) ultrasound assessment of the pelvis was made to exclude obvious pathology, before selection of a region of interest and acquisition of 3D data were carried out. The region of interest, which defines two of the dimensions (length and height) of the volume to be acquired and the midpoint of the resulting dataset, was defined in the longitudinal plane to ensure that the whole uterus and upper cervix were included. The third dimension of the volume dataset (width) was determined by the angle of acquisition, which was set to the maximum angle of 120
• . The automated mode was used for data acquisition, as this provides the maximum number of 2D image planes (each of which is used to reconstruct the 3D dataset) and therefore the highest image quality. The resulting multiplanar display was examined to ensure that the whole uterus was captured and the acquisition repeated if there was any doubt about the quality or completeness of the dataset. Once an adequate dataset had been acquired, it was saved to the hard drive of the ultrasound machine using a patient-specific coding system that did not include the name of the patient, in order to comply with the UK Data Protection Act. All analyses were performed on the ultrasound machine. The 3D dataset was initially displayed in the multiplanar view, which shows simultaneously the longitudinal, transverse and coronal planes of the acquired data in an orthogonal manner, so that each image is at 90
• to the other two images (Figure 1 ). Minimal data manipulation was required owing to the data acquisition technique, which meant that the longitudinal, transverse and coronal planes of the uterus were immediately evident in most cases. The dataset, however, was adjusted in all cases to ensure a standardized mid-coronal view. In this view, the endometrium was evident in all three planes, both the fundal aspect of the uterus and upper endometrial cavity were demonstrable in the coronal plane and the interstitial portions of both Fallopian tubes were displayed simultaneously. The uterine morphology and shape of the endometrial cavity were then assessed in the coronal plane and categorized as normal or abnormal. Abnormal uteri were categorized by type according to the modified AFS classification proposed by Salim et al. 6 ( Table 1 and Figures 2 and 3) . If the external contour of the uterus was uniformly convex or had an indentation of < 10 mm, but there was a cavity indentation, it was defined as arcuate or septate. Arcuate uterus was further defined as the presence of concave fundal indentation with a central point of indentation at an obtuse angle. Subseptate uterus was defined as the presence of a septum, not extending to the cervix, with the central point of the septum at an acute angle; if the septum extended to the internal os, the uterus was defined as septate. Uterine anomalies were then subclassified according to their severity. An arcuate uterus was considered a minor anomaly and all other anomalies, including subseptate, septate, didelphys, unicornuate and bicornuate uteri, were classified as major.
Assisted reproduction protocol
Assisted reproduction involved a long, down-regulation protocol using gonadotropin-releasing hormone agonist (500 μg/day of Buserelin (Suprefact; Aventis Pharma, Kent, UK) or 800 μg/day of Nafarelin (Synarel; Pharmacia, Milton Keynes, UK)) 7 days before the earliest anticipated date of menstruation. Following confirmation of pituitary suppression, defined as ovarian activity less than 1-cm follicle size and a serum estradiol level below 200 pmol/L, ovarian stimulation was commenced with either recombinant follicle-stimulating hormone (rFSH) (Gonal-F; Serono Pharmaceuticals Ltd, Feltham, UK) or purified urinary human menopausal gonadotropin (Menopur; Ferring Pharmaceuticals, Berks, UK). The starting dose used for stimulation was based on the subject's age (150 IU for women under 30 years of age, 225 IU for women aged between 30 and 38 years and 300 IU for women aged 38 years or more) according to local practice and the unit's standard operating protocol and adjusted according to the ovarian response, which was monitored by alternate-day TVS scans and serum estradiol measurements from the 5 th day of ovarian stimulation. Human chorionic gonadotropin (hCG) (6500 IU of Ovitrelle (Serono Pharmaceuticals Ltd) or 10 000 IU of Pregnyl (Organon Laboratories Ltd, Cambs, UK)) was administered when there were three or more follicles measuring 18 mm or more in diameter. Transvaginal oocyte retrieval was performed 36 h later. Fertilization was achieved using standard in-vitro fertilization or intracytoplasmic sperm injection, depending on the cause of subfertility and information derived from any previous treatment cycles. A maximum of three normally cleaved embryos were transferred into the uterus 48 h later or at the blastocyst stage. Luteal phase support was commenced (progesterone; 400 mg of Cyclogest (Actavis Ltd, Devon, UK)) and serum hCG level measured 16 days later to determine the outcome. If the pregnancy test was positive, defined as serum hCG above 50 IU/L, TVS was scheduled for 2 weeks later to confirm the presence of a gestational sac with or without a fetal pole and fetal heart activity (clinical pregnancy). Participants were subsequently followed up according to the requirements of the UK Human Fertilisation and Embryology Authority, including ascertainment of subsequent birth details. The study was limited to the first cycle of treatment.
Statistical analysis
SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data were compared using the unpaired Student's t-test or Fisher's exact test. Categorical variables were summarized using frequencies and percentages, and CIs were calculated using the modified Wald method 17 . Nominal variables were summarized by mean and SD if normally distributed and by median and lower-upper quartile if not. Bivariate and multiple logistic regression analyses were performed to evaluate the effect of the presence or absence of uterine anomalies, age, antral follicle count, AMH, arcuate uterus, major anomalies and single embryo transfer on the prediction of live birth. Data are given as mean ± SD or n (%). ICSI, intracytoplasmic sperm injection; IVF, in-vitro fertilization.
RESULTS
The clinic received 3941 referrals during the study period, from which a total of 2387 women were recruited. Reasons for non-participation included refusal to participate, ultrasound scan performed elsewhere, assisted reproduction not performed or previous uterine surgery ( Figure 4 ). Twelve patients were subsequently excluded because definitive diagnosis was not possible owing to limited views (n = 3), distortion of the endometrial cavity by fibroids (n = 7) or the presence of an in-situ intrauterine contraceptive device (n = 2). Thirty-three women required a further scan in the late follicular phase because of limited views at the time of the first scan. The final analysis included 2375 women, of whom 432 (18.2%) had a congenital uterine anomaly and 1943 (81.8%) had a normal uterus (controls). The baseline characteristics of the two study groups are summarized in Table 2 . Maternal age, levels of FSH and AMH and antral follicle count were similar between the two groups. Women with congenital uterine anomalies had significantly higher body mass index (BMI) and fewer previous deliveries than did the control group. Women with a normal uterus had more embryos/blastocysts replaced (P = 0.04) than did women with congenital uterine anomalies. No other significant difference related to the characteristics of the assisted reproduction cycle was observed between the groups (Table 3) .
Of the 2375 women who underwent assisted reproduction, a total of 1030 (43.4%) achieved clinical pregnancy, of whom 180 women had a congenital uterine anomaly and 850 had a normal uterus (Table 4) . Of these, 152 (84.4%) women with a uterine anomaly and 722 (84.9%) women with a normal uterus had a live birth. Thirty-five women were lost to follow-up (uterine-anomaly group, n = 5; controls, n = 30). The rates of clinical pregnancy and live birth were similar between women with a congenital uterine anomaly and controls. There was no difference in mode of delivery, sex of newborn or birth weight between the groups. However, women with congenital uterine anomalies were more likely to deliver preterm.
Subgroup analysis by type of uterine morphology is shown in Table 5 . The most common anomaly was an arcuate uterus (387/2375 (16.3%)) followed by a subseptate uterus (16/2375 (0.7%)). Women with an arcuate uterus had similar clinical pregnancy rate (P = 0.78) and live-birth rate (P = 0.91) to those with a normal uterus. Women with major anomalies had a statistically lower clinical pregnancy rate (P = 0.048) and live-birth rate (P = 0.042) than did controls. Pregnancy outcomes for women with canalization and unification defects are shown in Table S1 , and a comparison of reproductive outcomes in women with major anomalies vs those with a normal or arcuate uterus in Table S2 .
The results of logistic regression analysis adjusted for age, BMI, levels of AMH, antral follicle count and number and day of embryo transfer are shown in Table S3 . The results show that the presence of uterine anomalies as a whole (adjusted odds ratio (OR), 0.99 (95% CI, 0.76-1.29)) or the presence of an arcuate uterus (adjusted OR, 1.29 (95% CI, 0.97-1.71)) continued to have no impact on live-birth rates. There was a greater difference in the major-anomalies group after adjustment for the above parameters (adjusted OR, 0.16 (95% CI, 0.08-0.36) vs non-adjusted OR, 0.48 (95% CI, 0.24-0.98)).
DISCUSSION

Key results
When considered as a group, congenital uterine anomalies had no effect on the rate of clinical pregnancy or live birth after assisted reproduction. Secondary analysis demonstrated that an arcuate uterus had no effect on the rate of clinical pregnancy or live birth, but major uterine anomalies significantly worsened reproductive outcome. Women with a congenital uterine anomaly were less likely to have had a previous birth and more likely to deliver preterm.
Strengths and limitations of the study
This is the largest study reporting on live-birth outcomes in women with congenital uterine anomalies following assisted reproduction. A similar study conducted previously in our center reported only first-trimester miscarriage rates 14 . We acknowledge the inherent selection bias resulting from limiting recruitment to one center, which may have given a different prevalence of uterine anomalies than in the whole population; nonetheless, this should not affect the results of this study. A strength of the study is that women were prospectively recruited before pregnancy because of infertility. This limits our ability to relate uterine anomalies to fertility, but reduces the possibility of ascertainment bias by differential identification of women with miscarriage, preterm birth or other pregnancy complications.
Some baseline characteristics differed between the two groups (BMI, previous pregnancy history). BMI may be of relevance because it independently affects reproductive outcome, but differences were modest (mean BMI, 24.0-24.5 kg/m 2 ) and of doubtful clinical relevance. Confounding factors such as age, BMI, markers of ovarian reserve and number and day of embryo transfer, were accounted for by logistic regression analysis.
The study was powered to detect the prevalence of rarer uterine anomalies, thus no a-priori sample-size calculation was performed for secondary analyses. Despite the large number of women included in the study, there was still an insufficient number to allow us to assess the impact of major anomalies by subtype.
Using a single, well-defined classification system -the modified AFS classification system proposed by Salim et al. 6 -this study provides more reliable evidence for the prevalence and impact of uterine anomalies than did previous studies that did not state how anomalies were classified. However, this system has since been superseded by the ESHRE-ESGE and American Society for Reproductive Medicine (ASRM) systems. Comparing the study results using these classification systems would be interesting, but this was not possible for us as neither system had been published during the study period, and volume datasets were not available to allow reclassification of the congenital uterine anomalies.
The sonographers involved in the study were experienced, trained in image acquisition and the classification of uterine anomalies and followed a standard operating procedure; nonetheless, it was not possible to eliminate interrater variation. Using multiple sonographers makes this study comparable with clinical practice and highlights the importance of quality assurance in ultrasound assessment.
Interpretation
The lack of association between the presence of congenital uterine anomalies, when all types were considered together, and live birth is somewhat surprising. Current evidence from the most recent systematic review, suggests that women with an arcuate uterus have a higher rate of second-trimester miscarriage, and women with major uterine anomalies have higher rates of infertility, miscarriage, preterm birth, malpresentation at delivery and perinatal mortality 13 . Our findings are in broad agreement with those found in the literature, showing that major congenital uterine anomalies have a more detrimental effect on pregnancy outcome.
These results highlight the fundamental importance of accurate and reliable classification of uterine morphology.
Virtually all studies included in previous meta-analyses of the prevalence and effect of uterine anomalies on reproductive outcome used classification systems without morphometric criteria, based on subjective appearance alone. Not all anomalies have the same effect on reproductive outcome, so reliable classification systems should be adopted to allow comparison between studies and centers and prevent confusion. Indeed, this is demonstrated by the considerably higher than expected prevalence of arcuate uterus in our study, compared with the results of a previous meta-analysis (16% vs 1-10%) 9 . The most likely explanation for this discrepancy is the classification system followed, rather than the presence of a real difference between the studies. For example, in our study, the presence of any uterine cavity indentation, even as small as 1 mm, was classified as arcuate uterus. Studies relying on subjective appearance are likely to classify minor indentations as normal, and more pronounced indentations as subseptate.
Debate surrounding the existence and significance of an arcuate uterus has been longstanding, in part owing to confusion regarding classification and effects on reproductive outcomes. The original paper on the AFS classification asserted that 'the arcuate uterus appears to behave benignly' 5 . Now both the ESHRE-ESGE 7 and ASRM 12 classification systems regard this condition as a minor anomaly. Our findings provide some reassurance to women with an arcuate uterus that it has no effect on live-birth rate, supporting its exclusion from the category of uterine anomalies. However, we found that women with an arcuate uterus were more likely to deliver preterm. Furthermore, few studies have investigated the prevalence and effects of an arcuate uterus on preterm birth, and removal of this condition from the list of uterine anomalies may hinder further research in this area. In addition, concerns have been raised that removal of the arcuate uterus from the list of uterine anomalies may increase the number of minor anomalies reclassified as uterine septa 8 . The ESHRE-ESGE system defines a partial septate uterus as a midline indentation greater than 50% of the uterine wall thickness, while ASRM guidelines define it as an indentation of more than 15 mm 7, 12 . Neither of these competing definitions is derived from data on the effect on reproductive outcome. Indeed, many clinicians find this confusing, instead selecting to use their subjective impression to define uterine anomalies.
Ultimately, the question is whether there are any treatments for congenital uterine anomalies. At present, the only potential treatment is resection of a septum, but uncertainty remains regarding its safety and efficacy 18 . Currently, there are no completed randomized controlled trials evaluating the effect of hysteroscopic septum resection in women with septate uterus; the TRUST (http://www.studies-obsgyn.nl/trust) and SEP-TUM (ISRCTN28960271) trials are ongoing. Given our findings, we are concerned that the ESHRE-ESGE system has the potential to promote 'septal' resection for what appears to be a benign condition.
Future studies should be powered to establish the effect of major uterine anomalies on reproductive outcome, and to assess when cavity indentation becomes pathological. Single-center studies, involving rarer uterine anomalies, would be difficult; therefore, we propose establishment of a register of women to investigate their effect.
Conclusions
Congenital uterine anomalies as a whole, defined using the modified AFS classification system, do not affect rates of clinical pregnancy or live birth in women following assisted reproduction, but do increase the rate of preterm birth. The high prevalence of arcuate uterus in our study population is the likely explanation and, when excluded, the remaining major uterine anomalies significantly worsen pregnancy outcome. Therefore, different subtypes of uterine anomaly should not be grouped together, because they would appear to have different prognoses.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Pregnancy outcome in the canalization and unification defect groups Table S2 Reproductive outcome of women who had assisted reproduction. P-values relate to pregnancy and birth outcomes in women with major anomalies compared to the same values in women with a normal/arcuate uterus Table S3 Bivariate logistic regression analysis evaluating the effect of uterine anomalies as a whole, arcuate uteri and major anomalies vs normal uteri, calculated per woman treated for the outcome of live birth. Adjusted for age, body mass index, antral follicle count, anti-Müllerian hormone and number and day of embryo transfer
